CS277525B6 - Mixture against migraine - Google Patents

Abstract

The solution relates to an anti-migraine composition against migraine headaches of all types, which contains 150 to 400 mg of paracetamol, 150 to 350 mg acetylsalicylic acid v buffered form, 0.6 to 2.0 mg ergotamine tartaricum, 50 to 150 mg caffeine, 5 to 20 mg codeinum dihydrogenphosphoricum and 15 to 30 mg phenobarbitalum. The solution can be used in medicine in the field of neurology.

Description

The invention relates to an antimigraine composition which also acts in a state of full-blown migraine attack.

According to various world statistics, 5 to 10% of the population (mainly women aged 17 to 55) suffer from migraine headaches of various types. Patients are treated on an outpatient basis or are hospitalized. .

In the treatment of an acute migraine condition (the patient should be hospitalized according to the opinion of the majority of doctors), one-component drugs are administered, e.g. Cornutamine (ergotaminium tartaricum), Dihydergot (dihydroergotamine methanesulfonate), Protazine (promethasinium chloride), Diazepam (chlorodiazepoxide), Papaverine (papaverine hydrochloride), Indren (indomethacin); from multicomponent e.g. Ergofein (ergotaminium tartaricum + coffeinum), Bellaspon (ergotaminium tartaricum + radobelin + phenobarbital), Spasmoveralgin (aminophenazone + brominated + phenobarbital + papaverine hydrochloride + codeine dyhydrogenphosphenium phosphate + with citric acid).

To prevent seizures are used e.g. Clavigrenin (dihydroergotaminium mesylicum), Secatoxin (dihydroergotoxin), Lysenyl (lysuridium hydrogenmaleinicum), Cornutamine, Divascol (tolazolinium chloride), Sandomigran (pizotifenum).

The disadvantage of the preparations used in an acute attack is their poor effectiveness and unreliability, which lead to increased doses and thus side effects (heart, blood vessels, digestive tract, CNS). Products used as prevention in long-term treatments (several weeks to months) do not significantly reduce the frequency and intensity of seizures. Long-term administration of e.g. Sandomigran has a sedative effect, increased appetite, weight gain, paraesthesia, indigestion, reduced to zero effect after repeated treatments, as a result of which patients focus their treatment on suppressing acute conditions with high doses of analgesics, several times the therapeutic dose (multiple doses). 5 to 12 tablets at a time).

Despite great scientific progress, the problem of treating migraines (similar to other vasogenic diseases) is currently unresolved.

By several years of monitoring the effects of some hitherto used preparations as well as new drugs, it has been possible to prepare an antimigraine composition according to the invention which eliminates most of the disadvantages of previously used migraine drugs. The essence of the invention is that the antimigraine mixture contains in a single dose 150 to 400 mg of paracetamol, 150 to 350 mg of acetylsalicylic acid in buffered form, 0.6 to 2.0 mg of ergotaminium tartrate, 50 to 150 mg of caffeine, 5 to 20 mg codeine dihydrogen phosphorium and 15 to 30 mg of phenobarbitol, which is a gentle but surprisingly very effective mixture, with an effect of such intensity as has not been described so far.

This antimigraine mixture according to the invention, with relatively low amounts of the individual drugs, provides the desired effects not only in the migraine state in the as yet undeveloped state. stage, but also in the state of pine developed seizure, even where the previous treatment has not been successful.

When administered in the as-yet undeveloped stage of the aura, the effect begins in 10 to 25 minutes (depending on the stomach contents) and is definitive, i. the seizure does not develop. When administered in the stage of a fully developed migraine attack, the effect starts within 20 to 30 minutes, and in case of incomplete elimination (depending on the type of attack) it is possible to administer a dose after · 1 to 2 hours, which will definitely alleviate the attack. The need for a third dose to definitively eliminate the seizure is rare. By administering this mixture, the intervals between the individual seizures are even prolonged and their number is halved. By administering the antimigraine composition according to the invention only in acute conditions, i. 1 to 2 doses in a seizure (ie not preventive, long-term) reduces the risk of exceeding single and daily doses as well as the risk of side effects. The cooperation between the doctor and the patient is significantly improving, as after many, so far unsuccessful long-term treatments, he finds a way out of his condition.

The following examples illustrate but do not limit the scope of the invention.

Example 1

Migraine mixture (1)

paracetamol 250 mg acetylsalicylic acid 350 mg ergotamine tartrate 1.5 mg caffeine 50.0 mg codeinum dihydrogenphosphoricum 10.0 mg phenobarbitalum 15.0 mg

was prepared by mixing the individual components into a powder.

In the same manner, an antimigraine mixture (2) was prepared by mixing

paracetamol 350.0 mg acetylsalicylic acid 200.0 mg ergotaminium tartaricum 0.8 mg caffeine 150.0 mg codeinum dihydrogenphosphoricum 15.0 mg phenobarbitalum 25.0 mg

and finalizing into a tablet form.

The antimigraine mixtures (1,2) according to the invention were obtained with the following result:

test substance 1st patient 2nd patient 3rd patient 4th patient Sandomigran - - - - mixture (1) + - Φ +++ ++ mixture (2) Φ ++ Φ Φ

φ - has not been tested

- invaluable effect + effect at the level of others ++ strong positive effect +++ surprisingly ingested, account.

These results indicate that the antimigraine composition of the invention is more effective than all drugs used heretofore in acute attacks of moderate to severe. Due to the fact that the mixture is used only directly during an attack, possible side effects as well as addiction are reduced to a minimum.

The invention may find application in neurology in the treatment of all types of migraine headaches with typical symptomatology.

Claims (1)

PATENT CLAIMS An antimigraine mixture, characterized in that it contains e. 150 to 400 mg of paracetamol, 150 to 350 mg of acetylsalicylic acid in buffered form, 0.6 to 2.0 mg ergotamine tartaric acid, 50 to 150 mg of caffeine, 5 to 20 mg codeinum dihydrogenphosphoricum a 15 to 30 mg of phenobarbital.